BIOCRYST PHARMACEUTICALS INCBCRXEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 10.20% | 21.0M | ▲ +1.10pp | 2024-09-10 |
| The Vanguard Group | 10.02% | 20.7M | ▲ +0.21pp | 2024-11-07 |
| Avoro Capital Advisors LLC | 6.40% | 13.1M | — | 2024-02-14 |
| Baker Bros. Advisors LP | 4.94% | 10.1M | — | 2024-02-14 |
| STATE STREET CORPORATION | 4.30% | 8.8M | ▼ -1.94pp | 2024-10-17 |
Insider Transactions
Net 90d: −$4.52M · buys $0 / sells $4.52MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-06 | Sandeep Menon | Chief R&D Officer | Grant | 205.2K | $0.00 | $0 |
| 2026-03-20 | HEGGIE THERESA | Director | Option exercise | 49.9K | $6.30 | $314.6K |
| 2026-03-20 | HEGGIE THERESA | Director | Sell (open market) | 49.9K | $10.11 | $504.8K |
| 2026-03-16 | Barnes Alane P | Chief Legal Officer | Option exercise | 150.0K | $5.51 | $826.5K |
| 2026-03-16 | Barnes Alane P | Chief Legal Officer | Sell (open market) | 150.0K | $9.15 | $1.37M |
| 2026-03-02 | Stonehouse Jon P | Director | Option exercise | 306.0K | $3.22 | $985.3K |
| 2026-03-02 | Stonehouse Jon P | Director | Disposition | 306.0K | $8.64 | $2.64M |
| 2026-02-27 | Stonehouse Jon P | Director | Grant | 421 | $8.75 | $3.7K |
| 2026-02-27 | Milne Jill C. | Director | Grant | 528 | $8.75 | $4.6K |
| 2026-02-27 | MILANO VINCENT | Director | Grant | 848 | $8.75 | $7.4K |
1–10 of 12
Page 1 / 2